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Cancer is a major cause of mortality in
the modern world, with more than 10
million new cases every year. This out-
line is expected to rise in the next few
decades since the majority (59%) of peo-
ple diagnosed with cancer is aged over 65.
In fact, around one in three people will
be diagnosed with cancer throughout their
lifetime (Siegel et al., 2012; Bosetti et al.,
2013).
The foundation of cancer treatment
is surgery, chemotherapy, radiation,
antibody-blocking therapy, or a com-
bination of these therapies (Hanahan
and Weinberg, 2000). Still, many clinical
chemotherapeutic and radiotherapeutic
regimes are not exceptionally effective,
due to multidrug resistance mechanisms,
depending on the patient and the type of
tumor. Therefore, there is an urgent need
for more effective and valuable cancer
therapeutics, in order to reduce the impact
of the chemotherapeutic agents on the
healthy tissues by creating more selective
systems toward the cancerous cells (Alison,
2001; Perez-Tomas, 2006).
Multi-drug resistance (MDR) in can-
cer refers to the capacity of cancer cells
to survive or become resistant from treat-
ment of a wide variety of drugs. Cancer
chemotherapy has become progressively
sophisticated within the last years; how-
ever there are not any cancer therapies
100% effective against disseminated can-
cer. This is in fact a major problem once
approximately 70% of patients do not
respond to initial chemotherapy and the
five-year survival rate for these patients
is a low 10–30%. Relapse is also frequent
(Diseases, 2000).
Mechanisms of MDR include decreased
uptake of drugs, reduced intracellular
drug concentration by activation of the
efflux transporters, modifications in cellu-
lar pathways by altering cell cycle check-
points, increased metabolism of drugs,
induced emergency response genes to
impair apoptotic pathways and altered
DNA repair mechanisms (Gottesman,
2002). P-glycoprotein (P-gp) is the best
known membrane transporter used in
MDR and has been first described in
the late 1970s (Juliano and Ling, 1976).
Since then, the phenomenon of cancer
drug resistance became a hotspot of cancer
research (Gottesman, 2002; Ullah, 2008).
Despite of the discovery of multiple
new gene/protein expression signatures or
factors associated with drug resistance by
high throughput “-omics” technologies,
none of these findings has been useful in
producing efficient and specific diagnos-
tic assays or for improvement of updated
chemosensitizers. Clinical success has also
been limited due to issues regarding safety,
once one of the most common strate-
gies against MDR is the development of
ATP-binding cassette (ABC) transporter
inhibitors, which are poorly effective and
specific, increasing the toxicity associated
with chemotherapy (Lage, 2008).
Nanotechnology and nanomaterials in
particular, are expected to provide a range
of devices to treat cancer as their sizes are
well matched in size to biologic molecules
and structures found inside living cells
(Conde et al., 2012).
The development of nanoscale devices
and structures has provided major break-
throughs in monitoring and fighting can-
cer (Qian et al., 2008; Ren et al., 2012;
Conde et al., 2013). Cancer nanotechnol-
ogy offers a wealth of safety and inno-
vative tools to treat and diagnose cancer,
such as multifunctional, targeted devices
capable of bypassing crucial biological bar-
riers and to deliver multiple therapeutic
agents directly to cancer cells and adjacent
tissues around tumor microenvironment
(Sanvicens and Marco, 2008).
Nanoparticles (NPs) are usually pro-
duced to deliver and enhance the drug
concentration inside the cancer cells,
using both active and passive targeting.
(NPs) are excellent tumor-targeting vehi-
cles because of the unique inherent prop-
erty of solid tumors. Numerous tumors
present with defective vasculature and
poor lymphatic drainage, due to their
rapid growth, resulting in an enhanced
permeability and retention (EPR) effect.
This effect allows (NPs) to accumulate
preferably at the tumor site. Once the
tumor is directly connected to the main
blood circulation system, multifunctional
(NPs) may exploit several characteristics
of the newly formed vasculature and effi-
ciently target tumors (Conde et al., 2012;
Schroeder et al., 2012). This effect con-
stitutes one of the major advantages of
(NPs) against MDR mechanisms. In fact,
lipid (NPs) and nanocapsules, polymeric
(NPs), metal (NPs), dendrimers and lipo-
somes have been reported to circumvent
drug resistance (Dong andMumper, 2010)
(Figure 1).
The most common nanomaterials to
use against (P-gp) and ABC transporters
resistance are non-ionic surfactants (i.e.,
poly(ethylene glycol), Tween 80® and
Pluronics®) that usually form hydrogel
bonds with the protein to escape from
the recognition and therefore increase the
uptake of the nanoformulated drug (Gao
et al., 2012). The ABC transporters are
also expressed in normal cells and so it
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FIGURE 1 | Nanotechnology against multidrug resistance. Smart nanomaterials (i.e., liposomes,
polymeric, magnetic, silica, and gold nanoparticles functionalized with MDR inhibitors and targeting
moieties) can be used to circumvent essential MDR mechanisms, by increasing drug efflux and
metabolism and activating DNA repair and apoptotic pathways.
is necessary to inhibit these drug efflux
transporters in tumor tissues preferen-
tially, while minimizing the inhibition in
normal tissues (Patel et al., 2013).
Some of these nanomaterials have been
used to overcome drug efflux by drug
transporters, increasing the drug reten-
tion effect in cancer cells. These systems
comprise the nanoformultation (specially
with liposomes, nanodiamonds, meso-
porous silica nanoparticles) of siRNAs and
drugs like doxorubicin (DOX), used to
hamper cancer progression, inhibiting the
drug detoxification, by suppressing cell
defense mechanisms, activating apopto-
sis and DNA repair (Minko et al., 1999;
Chen et al., 2009, 2010; Chow et al.,
2011).
Other drugs like vincristine, verapamil,
cyclosporin, paclitaxel, oxaliplatin, cis-
platin, and curcumin have been delivered
using polymeric (NPs) and nanoemulsions
made of surfactants (Soma et al., 2000;
Devalapally et al., 2007; van Vlerken et al.,
2007; Abu Lila et al., 2009; Ganta and
Amiji, 2009; Song et al., 2009; Yadav et al.,
2009; Aryal et al., 2010).
This combinatorial delivery of multi-
ple drugs and MDR inhibitors opens up
a huge amount of schemes to target the
comprehensive mechanisms of MDR espe-
cially via the EPR effect, and at the same
time it lifts up some important concerns
about this approach.
Although most of these studies
reported a co-delivery of multiple agents
in the same nanoparticle such as siRNAs,
chemotherapeutic drugs, antibodies and
other MDR inhibitors, these formulations
are far from achieving excellent results.
This happens once the majority of drugs
such as paclitaxel are hydrophobic and the
MDR inhibitors like siRNAs anti-MDR
associated genes are hydrophilic. This
fact impairs one of the most amazing
characteristic of the nanoparticle sys-
tems that is the high loading capability in
the same formulation. Another problem
with the loading of multiple drugs in the
same nanoformulation is the molar ratios
between molecules that are often incom-
parable and sometimes very difficult to
control and quantify. This is a key element
in dosage optimization and maximization
of the combinatorial effects along with the
nanoformulated composites (Creixell and
Peppas, 2012; Gao et al., 2012).
Moreover, the interaction between
chemotherapeutic drugs and MDR
inhibitors (i.e., siRNAs) may occur when
using coadministration. In fact, some of
the drugs can strongly influence endoso-
mal escape and siRNA recognition by the
RNA Induced Silencing Complex (RISC),
which are crucial obstacles/limitations
for translation of RNAi into clinical
setting (Lee et al., 2013). This mutual
interactions between drugs and siR-
NAs need to be further explored and
optimized.
This raises another challenge, which is
the endosomal escaping of the nanofor-
mulated drugs. Upon endocytosis the
NPs-drugs usually go to the lysosomal
and endosomal compartments, facing a
strong acidic and enzymatic environment
(Hu and Zhang, 2009). A biomolecule
that bypasses the endosome would greatly
increase the therapeutic effect. For exam-
ple, a fusogenic peptide would promote
endosomal escape by a pH-responsive
mechanism in which the peptide becomes
protonated at the acidic pH of the endo-
some, destabilizing the endosomal mem-
brane when the protonated peptide fuses
with it, enabling the delivery of the siR-
NAs to the cytoplasm without suffering
degradation. Poly(ethylene imine) (PEI)
is a cationic polymer and is also used as
carrier for siRNA due to its high siRNA
binding capacity and its proton sponge
effect for endosomal escape (Creixell and
Peppas, 2012).
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However, some effective nanoparticle
formulations (in particular liposomes and
micelles) have been reported using the
endocytic uptake of drug to avoid MDR
(Thierry et al., 1993; Huwyler et al., 2002;
Rapoport et al., 2002). This occurs since
formulated/encapsulated drugs are more
effective than free drugs, as sometimes
they have more cytotoxicity to resistant
cancer cells and/or improved internaliza-
tion yields (Huwyler et al., 2002; Gabizon
et al., 2003).
An alternative to the use of siRNA-NPs
are the antisense oligodeoxynucleotides
nanoformulations, once are more stable in
biological matrices and have more resis-
tance to enzymatic degradation (Conde
et al., 2010; Wang et al., 2010).
In addition of active targeting, the long
circulating half-life and drug release kinet-
ics are important aspects of an effective
strategy to combat MDR. In fact, the rate
of drug release from the NP decides their
therapeutic effectiveness. When fast drug
release may lead to their lost while in
blood stream circulation, a slow kinetic
may predispose cancer cells to more resis-
tance once they may not compete with the
drug efflux pumps (Hu and Zhang, 2009).
To increase life-time, long circulating-
NPs are usually coated with poly(ethylene
glycol) (PEG), which has the ability
to circulate for a prolonged period of
time to allow efficient target of a par-
ticular cell/tissue/organ and retards the
uptake by the macrophages and mono-
cytes, from the reticuloendothelial system
(RES) (Kommareddy et al., 2005; Uchida
et al., 2005).
Concerning the stimuli-responsive
drug release, pH-sensitive triggers are the
most common strategies once tumoral
tissues are well known for presenting
acidic conditions, as well as the lyso-
somal and endosomal compartments,
which represent a strong advantage for
selective drug release. Several nanoformu-
lations of pH-triggered drug release have
been reported, especially those using pH-
sensitive liposomes (Fattal et al., 2004),
polymeric (NPs) (Roux et al., 2002),
micelles (Lee et al., 2008) and hydro-
gels (Griset et al., 2009). Generally, (NPs)
are coated with biomolecules (i.e., phos-
phatidylethanolamine, poly(ethylene gly-
col), poly(L-histidine), poly(L-lactic acid),
polymethacrylates, poly(amidoamine))
that, when protonated, destabilize the for-
mulation (that become leaky in acidic
environment) leading to the acceler-
ated/controlled intracellular drug release.
This kinetic release overwhelms the (P-gp)
drug efflux pumps (Hu and Zhang, 2009).
Although the use of organic (NPs) such
as liposomes, lipids, micelles, and poly-
meric (NPs) constitute the major strategy
to deliver high amounts of drugs andMDR
inhibitors, the use of inorganic (NPs) to
reverse MDR in cancer has also been
reported.
The most frequent systems usually
combine silica (Rigby, 2007; Chen et al.,
2009), magnetic (Cheng et al., 2011; Singh
et al., 2011; Klostergaard and Seeney,
2012) or gold (NPs) (Dreaden et al., 2012;
Tomuleasa et al., 2012) with specific drugs
and siRNAs. The silica (NPs) are ideal can-
didates for the loading of large amounts
of drugs and other components, due to
high surface area to volume ratio and
large pore volume. The magnetic (NPs)
allow for physical/magnetic enhance-
ment of the passive mechanisms for the
accumulation of magnetic-responsive
(NPs) into tumor tissue, leading to
increase cellular uptake. Gold (NPs) also
have shape/size-dependent optoelectronic
properties and the endosomal-based route
for gold nanoparticle cellular uptake is
one of the main advantages for overcome
MDR (Ayers and Nasti, 2012; Creixell and
Peppas, 2012).
As described above, an extensive knowl-
edge has been gathered in the emerging
field of nanomaterials to overcome mul-
tidrug resistance mechanisms. Many of
the drugs available to circumvent MDR
were in the past unavailable to target
this mechanism due to low solubility
and/or stability. Nanomaterials made these
drugs a possible strategy to target MDR.
However, many anti-cancer drugs have
never been used in nanomedicine (Dong
and Mumper, 2010). Moreover, nano-
materials have also provided an effec-
tive platform to deliver high loads of
drugs (thus lower chances of resistance)
in a specific and controlled way (using
pH-responsive and stimuli-sensitive), with
surface-modified to improve circulation
time, preventing the uptake by the RES.
Another advantage of using nanomaterials
for MDR regression is the drastic reduc-
tion of the IC(50) value for most of the
nanoformulated drugs, reducing the clin-
ical doses of the conventional chemother-
apeutic agents, which show high levels of
cytotoxicity. This allows the expansion of
the anticancer therapeutic window.
However, many challenges involved in
biocompatibility and specificity of nano-
materials against MDR need to be fur-
ther investigated. Other crucial issues
embrace the fact that agents that can
reduce MDR in vitro, are sometimes use-
less in patients, probably because some
drugs get entrapped in circulation by
serum proteins, for example. In addition,
new nanoparticle-based targeting moieties
such as antibodies, minibodies and pep-
tides should be explored as an additive
effect of EPR.
Moreover, it is important to realize that
cancer cells need to lose their chemopro-
tective features mediated byMDR genes, at
the same time the chemotherapy-sensitive
non-cancerous cells (i.e., bone marrow
stem cells) need to be protected from the
effects of chemotherapeutic agents. In fact,
the destruction of these cells constitutes
the single most important dose-limiting
toxicity factor in cancer therapy. If we
could repopulate the blood system with
chemoresistant blood cells the patients
could receive higher doses of anticancer
agents than could be given normally.
This raises the important issue of
the specificity and toxicity of nano-
materials as one of the major obsta-
cles to treat multidrug-resistant tumors.
Therefore, any nanoformulation that tar-
get MDR must do so in a way that is
tumoral specific, in order not to affect the
normal function of healthy cells. This may
be achieved using, for example, effective
targeting ligands combined with valuable
pro-drugs.
Some of the described drug nanofor-
mulations here are now in human clinical
trials. So it is therefore predictable that
nanomaterials against MDR will eventu-
ally become commonplace in the oncology
clinic in the near future.
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